Keymed Biosciences Announces Strong Interim Results for 2025 with Accelerated Commercialization and R&D Momentum #China #Chengdu #Stapokibart #Keymed #R&D_Progress
0
0
0
0
Keymed Biosciences Announces Strong Interim Results for 2025 with Accelerated Commercialization and R&D Momentum #China #Chengdu #Stapokibart #Keymed #R&D_Progress
Groundbreaking Phase III Results of Stapokibart for Treating Seasonal Allergic Rhinitis Published in Nature Medicine #China #Chengdu #Stapokibart #Allergic_Rhinitis #Keymed
Keymed Biosciences Receives Approval for Stapokibart Treatment of Seasonal Allergic Rhinitis #China #Chengdu #Stapokibart #Keymed #Allergy_Treatment